Why the study?
Does epirubicin exhibit defective conversion to ROS and secondary alcohol metabolites compared to doxorubicin in human heart models?
Population
Translational model of the human heart using small myocardial samples from cardiac surgery patients…
Comparison
Epirubicin at clinically relevant concentrations vs Doxorubicin at clinically relevant concentrations
Design
Preclinical
Authors
Loading...
May explain reduced epirubicin cardiotoxicity in animals; hypothesis-generating for human cardiac models and should not yet change practice.
Does epirubicin exhibit defective conversion to ROS and secondary alcohol metabolites compared to doxorubicin in human heart models?
Epirubicin induces less cardiotoxicity than doxorubicin due to vesicular sequestration preventing ROS formation and impaired efficiency of electron addition reducing toxic alcohol metabolites.
Salvatorelli et al. (2006) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: